<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01669434</url>
  </required_header>
  <id_info>
    <org_study_id>369-12-FB</org_study_id>
    <nct_id>NCT01669434</nct_id>
  </id_info>
  <brief_title>Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery</brief_title>
  <official_title>Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and
      including the morning of a non-cardiac, non-vascular surgery will experience more
      intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

      Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and
      including the morning of a non-cardiac, non-vascular surgery will experience better
      postoperative control of hypertension than those who transiently hold their chronic ACEI
      preoperatively.

      Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and
      including the morning of a non-cardiac, non-vascular surgery will experience less acute renal
      failure than those who transiently hold their chronic ACEI preoperatively.

      Secondary research hypothesis #3: In the subgroup of patients with a preoperative systolic
      blood pressure less than 110 mmHg, those who continue their chronic ACEI therapy up to and
      including the morning of a non-cardiac, non-vascular surgery will experience more
      intraoperative hypotension than those who transiently hold their chronic ACEI preoperatively.

      Secondary research hypothesis #4: In the subgroup of patients above the age of 64, those who
      continue their chronic ACEI therapy up to and including the morning of a non-cardiac,
      non-vascular surgery will experience more intraoperative hypotension than those who
      transiently hold their chronic ACEI preoperatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine if transient discontinuation of angiotensin
      converting enzyme inhibitors (ACEIs) is necessary prior to non-cardiac, non-vascular surgery.
      ACEIs have been associated with intraoperative hypotension during vascular and cardiac
      surgeries. Patients presenting to the University of Nebraska Medical Center Pre-Anesthesia
      Screening (PAS) Clinic who are on chronic ACEI therapy will be eligible for enrollment.
      Subjects will be randomized to either omit or continue their ACEI preoperatively. The outcome
      of interest is intraoperative hypotension defined as a systolic blood pressure less than 80
      mmHg. Blood pressure will be followed not only throughout surgery, but also during recovery
      and the remainder of hospitalization. Renal function will be assessed with creatinine
      measurements in the PAS clinic and on the first postoperative day. No follow-up is planned
      beyond discharge from the hospital.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Interoperative Hypotension</measure>
    <time_frame>During anesthesia, an expected average of 3 hours.</time_frame>
    <description>Systolic Blood Pressure under 80 mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Renal Failure</measure>
    <time_frame>Arrival in post-anesthesia care unit (PACU) to hospital discharge, an expected average of 4 days.</time_frame>
    <description>Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Blood Pressure Subgroup</measure>
    <time_frame>During anesthesia, an expected average of 3 hours.</time_frame>
    <description>Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Older Age Subgroup</measure>
    <time_frame>During anesthesia, an expected average of 3 hours.</time_frame>
    <description>Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Hypertension</measure>
    <time_frame>Arrival in PACU to hospital discharge, an expected average of 4 days.</time_frame>
    <description>Any systolic blood pressure greater than 180 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Hypotension</measure>
    <time_frame>Arrival in PACU to hospital discharge, an expected average of 4 days.</time_frame>
    <description>Any systolic blood pressure less than 90 mmHg</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Hypotension on Induction</condition>
  <arm_group>
    <arm_group_label>ACEI continuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will be randomized to continue their chronic angiotensin converting enzyme inhibitor without interruption preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACEI omission</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this arm will be told to omit their final preoperative chronic angiotensin converting enzyme inhibitor dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI continuation</intervention_name>
    <description>These chronic medications will be taken without interruption preoperatively.</description>
    <arm_group_label>ACEI continuation</arm_group_label>
    <other_name>quinapril</other_name>
    <other_name>Accupril</other_name>
    <other_name>perindopril</other_name>
    <other_name>Aceon</other_name>
    <other_name>ramipril</other_name>
    <other_name>Altace</other_name>
    <other_name>benazepril</other_name>
    <other_name>Lotensin</other_name>
    <other_name>captopril</other_name>
    <other_name>Capoten</other_name>
    <other_name>enalapril</other_name>
    <other_name>Vasotec</other_name>
    <other_name>fosinopril</other_name>
    <other_name>Monopril</other_name>
    <other_name>lisinopril</other_name>
    <other_name>Prinivil</other_name>
    <other_name>Zestril</other_name>
    <other_name>trandolapril</other_name>
    <other_name>Mavik</other_name>
    <other_name>moexipril</other_name>
    <other_name>Univasc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI omission</intervention_name>
    <description>Although taken chronically by patients in this intervention, the final preoperative dose of these medications will be omitted, whether it was scheduled for the morning of surgery or the day prior.</description>
    <arm_group_label>ACEI omission</arm_group_label>
    <other_name>quinapril</other_name>
    <other_name>Accupril</other_name>
    <other_name>perindopril</other_name>
    <other_name>Aceon</other_name>
    <other_name>ramipril</other_name>
    <other_name>Altace</other_name>
    <other_name>benazepril</other_name>
    <other_name>Lotensin</other_name>
    <other_name>captopril</other_name>
    <other_name>Capoten</other_name>
    <other_name>enalapril</other_name>
    <other_name>Vasotec</other_name>
    <other_name>fosinopril</other_name>
    <other_name>Monopril</other_name>
    <other_name>lisinopril</other_name>
    <other_name>Prinivil</other_name>
    <other_name>Zestril</other_name>
    <other_name>trandolapril</other_name>
    <other_name>Mavik</other_name>
    <other_name>moexipril</other_name>
    <other_name>Univasc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referred to the University of Nebraska Medical Center Pre-Anesthesia Screening Clinic
             for preoperative evaluation.

          -  Above referral must be in anticipation of a non-cardiac, non-vascular surgery.

          -  Must have been on ACE-Inhibitor therapy for at least six weeks.

        Exclusion Criteria:

          -  Hypotension (systolic blood pressure &lt; 90 or diastolic blood pressure &lt;60) at the time
             of preoperative evaluation

          -  Uncontrolled Hypertension (systolic blood pressure &gt; 150 or diastolic blood pressure &gt;
             95) at the time of preoperative evaluation

          -  Surgery during which vasopressor use is anticipated (carotid endarterectomy, major
             abdominal operations, orthopedic oncology)

          -  Surgery for pathology related to vasoactive substances (carcinoid, pheochromocytoma)

          -  Left Ventricular ejection fraction less than 40%

          -  Clinical evidence of decompensated heart failure at the time of preoperative
             evaluation

          -  End-stage renal disease

          -  Organ transplant surgeries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason F Shiffermiller, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>McConachie I, Healy TE. ACE inhibitors and anaesthesia. Postgrad Med J. 1989 May;65(763):273-4. Review.</citation>
    <PMID>2692007</PMID>
  </reference>
  <reference>
    <citation>Coriat P, Richer C, Douraki T, Gomez C, Hendricks K, Giudicelli JF, Viars P. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology. 1994 Aug;81(2):299-307.</citation>
    <PMID>8053578</PMID>
  </reference>
  <reference>
    <citation>Comfere T, Sprung J, Kumar MM, Draper M, Wilson DP, Williams BA, Danielson DR, Liedl L, Warner DO. Angiotensin system inhibitors in a general surgical population. Anesth Analg. 2005 Mar;100(3):636-44, table of contents.</citation>
    <PMID>15728043</PMID>
  </reference>
  <reference>
    <citation>Pigott DW, Nagle C, Allman K, Westaby S, Evans RD. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth. 1999 Nov;83(5):715-20.</citation>
    <PMID>10690132</PMID>
  </reference>
  <reference>
    <citation>Steiner CA, Karaca Z, Moore BJ, Imshaug MC, Pickens G. Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014: Statistical Brief #223. 2017 May. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK442035/</citation>
    <PMID>28722845</PMID>
  </reference>
  <reference>
    <citation>Rate of all-listed procedures for discharges from short-stay hospitals, by procedure category and age: United States, 2010. 2010.</citation>
  </reference>
  <reference>
    <citation>Turan A, You J, Shiba A, Kurz A, Saager L, Sessler DI. Angiotensin converting enzyme inhibitors are not associated with respiratory complications or mortality after noncardiac surgery. Anesth Analg. 2012 Mar;114(3):552-60. doi: 10.1213/ANE.0b013e318241f6af. Epub 2012 Jan 17.</citation>
    <PMID>22253266</PMID>
  </reference>
  <reference>
    <citation>Mascha EJ, Yang D, Weiss S, Sessler DI. Intraoperative Mean Arterial Pressure Variability and 30-day Mortality in Patients Having Noncardiac Surgery. Anesthesiology. 2015 Jul;123(1):79-91. doi: 10.1097/ALN.0000000000000686.</citation>
    <PMID>25929547</PMID>
  </reference>
  <reference>
    <citation>Walsh M, Devereaux PJ, Garg AX, Kurz A, Turan A, Rodseth RN, Cywinski J, Thabane L, Sessler DI. Relationship between intraoperative mean arterial pressure and clinical outcomes after noncardiac surgery: toward an empirical definition of hypotension. Anesthesiology. 2013 Sep;119(3):507-15. doi: 10.1097/ALN.0b013e3182a10e26.</citation>
    <PMID>23835589</PMID>
  </reference>
  <reference>
    <citation>Bertrand M, Godet G, Meersschaert K, Brun L, Salcedo E, Coriat P. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg. 2001 Jan;92(1):26-30.</citation>
    <PMID>11133595</PMID>
  </reference>
  <reference>
    <citation>Roshanov PS, Rochwerg B, Patel A, Salehian O, Duceppe E, Belley-Côté EP, Guyatt GH, Sessler DI, Le Manach Y, Borges FK, Tandon V, Worster A, Thompson A, Koshy M, Devereaux B, Spencer FA, Sanders RD, Sloan EN, Morley EE, Paul J, Raymer KE, Punthakee Z, Devereaux PJ. Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort. Anesthesiology. 2017 Jan;126(1):16-27.</citation>
    <PMID>27775997</PMID>
  </reference>
  <reference>
    <citation>Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, Davila-Roman VG, Gerhard-Herman MD, Holly TA, Kane GC, Marine JE, Nelson MT, Spencer CC, Thompson A, Ting HH, Uretsky BF, Wijeysundera DN; American College of Cardiology; American Heart Association. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014 Dec 9;64(22):e77-137. doi: 10.1016/j.jacc.2014.07.944. Epub 2014 Aug 1.</citation>
    <PMID>25091544</PMID>
  </reference>
  <reference>
    <citation>Kristensen SD, Knuuti J, Saraste A, Anker S, Bøtker HE, Hert SD, Ford I, Gonzalez-Juanatey JR, Gorenek B, Heyndrickx GR, Hoeft A, Huber K, Iung B, Kjeldsen KP, Longrois D, Lüscher TF, Pierard L, Pocock S, Price S, Roffi M, Sirnes PA, Sousa-Uva M, Voudris V, Funck-Brentano C; Authors/Task Force Members. 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014 Sep 14;35(35):2383-431. doi: 10.1093/eurheartj/ehu282. Epub 2014 Aug 1.</citation>
    <PMID>25086026</PMID>
  </reference>
  <reference>
    <citation>Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.</citation>
    <PMID>17331245</PMID>
  </reference>
  <reference>
    <citation>Monk TG, Bronsert MR, Henderson WG, Mangione MP, Sum-Ping ST, Bentt DR, Nguyen JD, Richman JS, Meguid RA, Hammermeister KE. Association between Intraoperative Hypotension and Hypertension and 30-day Postoperative Mortality in Noncardiac Surgery. Anesthesiology. 2015 Aug;123(2):307-19. doi: 10.1097/ALN.0000000000000756. Erratum in: Anesthesiology. 2016 Mar;124(3):741-2.</citation>
    <PMID>26083768</PMID>
  </reference>
  <reference>
    <citation>Kheterpal S, Khodaparast O, Shanks A, O'Reilly M, Tremper KK. Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery. J Cardiothorac Vasc Anesth. 2008 Apr;22(2):180-6. doi: 10.1053/j.jvca.2007.12.020.</citation>
    <PMID>18375317</PMID>
  </reference>
  <reference>
    <citation>Twersky RS, Goel V, Narayan P, Weedon J. The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patients. Anesth Analg. 2014 May;118(5):938-44. doi: 10.1213/ANE.0000000000000076.</citation>
    <PMID>24681657</PMID>
  </reference>
  <reference>
    <citation>Tan TW, Eslami MH, Kalish JA, Eberhardt RT, Doros G, Goodney PP, Cronenwett JL, Farber A; Vascular Study Group of New England. The need for treatment of hemodynamic instability following carotid endarterectomy is associated with increased perioperative and 1-year morbidity and mortality. J Vasc Surg. 2014 Jan;59(1):16-24.e1-2. doi: 10.1016/j.jvs.2013.07.025. Epub 2013 Aug 30.</citation>
    <PMID>23994095</PMID>
  </reference>
  <reference>
    <citation>Lee SM, Takemoto S, Wallace AW. Association between Withholding Angiotensin Receptor Blockers in the Early Postoperative Period and 30-day Mortality: A Cohort Study of the Veterans Affairs Healthcare System. Anesthesiology. 2015 Aug;123(2):288-306. doi: 10.1097/ALN.0000000000000739.</citation>
    <PMID>26200181</PMID>
  </reference>
  <reference>
    <citation>Drenger B, Fontes ML, Miao Y, Mathew JP, Gozal Y, Aronson S, Dietzel C, Mangano DT; Investigators of the Ischemia Research and Education Foundation; Multicenter Study of Perioperative Ischemia Research Group. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality. Circulation. 2012 Jul 17;126(3):261-9. doi: 10.1161/CIRCULATIONAHA.111.059527. Epub 2012 Jun 19.</citation>
    <PMID>22715473</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2012</study_first_posted>
  <results_first_submitted>October 9, 2017</results_first_submitted>
  <results_first_submitted_qc>November 8, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Jason Shiffermiller, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Perioperative Period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypotension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Captopril</mesh_term>
    <mesh_term>Quinapril</mesh_term>
    <mesh_term>Trandolapril</mesh_term>
    <mesh_term>Fosinopril</mesh_term>
    <mesh_term>Moexipril</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ACEI Omission</title>
          <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or day before surgery, whenever the last preoperative dose would normally occur.</description>
        </group>
        <group group_id="P2">
          <title>ACEI Continuation</title>
          <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="137"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACEI Omission</title>
          <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
        </group>
        <group group_id="B2">
          <title>ACEI Continuation</title>
          <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="137"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="275"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="26" upper_limit="91"/>
                    <measurement group_id="B2" value="63.7" lower_limit="31" upper_limit="86"/>
                    <measurement group_id="B3" value="63.9" lower_limit="26" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Am Indian/Alaska</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Never</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Current</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Society of Anesthesiologists classification</title>
          <description>Scale range 1-6 I A normal healthy patient Healthy, non-smoking, no or minimal alcohol use 2 A patient with mild systemic disease 3 A patient with severe systemic disease 4 A patient with severe systemic disease that is a constant threat to life 5 A moribund patient who is not expected to survive without the operation 6 A declared brain-dead patient whose organs are being removed for donor purposes</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="B2" value="2.8" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="B3" value="2.8" lower_limit="1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative NSAID use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>preoperative systolic BP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136.6" lower_limit="99" upper_limit="187"/>
                    <measurement group_id="B2" value="136.3" lower_limit="102" upper_limit="184"/>
                    <measurement group_id="B3" value="136.5" lower_limit="99" upper_limit="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hypertension history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>congestive heart failure history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Additional antihypertensive</title>
          <description>Use of at least one additional antihypertensive medication in addition to an angiotensin converting enzyme inhibitor at the time of enrollment.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Interoperative Hypotension</title>
        <description>Systolic Blood Pressure under 80 mmHg</description>
        <time_frame>During anesthesia, an expected average of 3 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACEI Omission</title>
            <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
          </group>
          <group group_id="O2">
            <title>ACEI Continuation</title>
            <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Interoperative Hypotension</title>
          <description>Systolic Blood Pressure under 80 mmHg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Renal Failure</title>
        <description>Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level</description>
        <time_frame>Arrival in post-anesthesia care unit (PACU) to hospital discharge, an expected average of 4 days.</time_frame>
        <population>Missing outcome data for 37 patients, 18 in the ACEI omission arm and 19 in the ACEI continuation arm</population>
        <group_list>
          <group group_id="O1">
            <title>ACEI Omission</title>
            <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
          </group>
          <group group_id="O2">
            <title>ACEI Continuation</title>
            <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Renal Failure</title>
          <description>Creatinine increase of more than 0.3 mg/dl or more than 50% from preoperative level</description>
          <population>Missing outcome data for 37 patients, 18 in the ACEI omission arm and 19 in the ACEI continuation arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Blood Pressure Subgroup</title>
        <description>Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg.</description>
        <time_frame>During anesthesia, an expected average of 3 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACEI Omission</title>
            <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
          </group>
          <group group_id="O2">
            <title>ACEI Continuation</title>
            <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Low Blood Pressure Subgroup</title>
          <description>Only patients with systolic blood pressure less than 110 at preoperative evaluation will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>2.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Older Age Subgroup</title>
        <description>Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg</description>
        <time_frame>During anesthesia, an expected average of 3 hours.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACEI Omission</title>
            <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
          </group>
          <group group_id="O2">
            <title>ACEI Continuation</title>
            <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Older Age Subgroup</title>
          <description>Only patients above the age of 64 will be included in this analysis. The outcome is the same as the primary outcome: Intraoperative Systolic Blood Pressure under 80 mmHg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Hypertension</title>
        <description>Any systolic blood pressure greater than 180 mmHg.</description>
        <time_frame>Arrival in PACU to hospital discharge, an expected average of 4 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACEI Omission</title>
            <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
          </group>
          <group group_id="O2">
            <title>ACEI Continuation</title>
            <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Hypertension</title>
          <description>Any systolic blood pressure greater than 180 mmHg.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>1.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.14</ci_lower_limit>
            <ci_upper_limit>3.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Hypotension</title>
        <description>Any systolic blood pressure less than 90 mmHg</description>
        <time_frame>Arrival in PACU to hospital discharge, an expected average of 4 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ACEI Omission</title>
            <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
          </group>
          <group group_id="O2">
            <title>ACEI Continuation</title>
            <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Hypotension</title>
          <description>Any systolic blood pressure less than 90 mmHg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>Fisher Exact</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.28</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Hospitalization, expected duration 4 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACEI Omission</title>
          <description>Patients randomized to this arm will be told to hold their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI omission: These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery or evening before surgery, whenever the last preoperative dose would normally occur.</description>
        </group>
        <group group_id="E2">
          <title>ACEI Continuation</title>
          <description>Patients in this arm will be randomized to take their final preoperative angiotensin converting enzyme inhibitor dose.
ACEI continuation: These chronic medications will be given without interruption preoperatively.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>MACE</sub_title>
                <description>Major Adverse Cardiac Event. A composite of acute coronary syndrome, acute heart failure, or new-onset arrhythmia</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Management decisions were made by the treatment which was not blinded to allocation; Intraoperative hypotension is an intermediate measure but one that has known associations with adverse outcomes, including mortality.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jason Shiffermiller</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>402-559-7299</phone>
      <email>jshiffermiller@unmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

